Dakota, based in
Dakota said the Phase II Small Business Innovation Research grant will help it "accelerate ... plans" to commercialize products for high-throughput and high-content screening in drug discovery.
The assays Dakota is developing "aim to overcome false positives caused by fluorescence interferences commonly encountered in high-throughput screening," the company said in a statement. Its lifetime measurement technique, which Dakota said "provides enhanced multiplexing capabilities," will also be used to develop assays that are suited to multi-parameter analysis.